Cue Biopharma, Inc. (CUE) stock
Close on Nov 11, 2026Market cap $135.55MP/E –Yield –
Cue Biopharma, Inc. grew revenue 354.4% to $37.65M over the twelve months to Jun 30, 2026. Free cash flow was -$50.17M. At the latest close the market valued the company at $135.55M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $135.55M
- P/E ratio
- –
- Price to sales
- 3.60
- Price to book
- 58.68
- Dividend yield
- –
- Free cash flow yield
- -37.01%
Fundamentals
- Revenue
- $37.65M
- Net income
- -$164.11M
- EPS, diluted
- -$26.88
- Free cash flow
- -$50.17M
- Book value per share
- $0.36
- Diluted shares
- 6M
Trading
- Next earnings
- Nov 11, 2026 (estimated, after the close)
- Previous close
- $18.76
- Open
- $19.24
- Day's range
- $18.51 – $19.99
- Volume
- 122,973
- Average volume (20 days)
- 138,848
- Beta (5 years)
- 2.36
- 52-week range
- $4.97 – $45.50
- RSI (14 days)
- 43.4
- Volatility (1 year)
- 202.3%
- Relative volume
- 0.52×
- WACC
- 16.7%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CUE | S&P 500 | Difference | CUE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.5% | -2.4% | −30.1 pts | ||
| 3 months | -33.9% | -1.2% | −32.8 pts | ||
| Year to date | +103.6% | +12.3% | +91.4 pts | ||
| 1 year | -8.9% | +12.4% | −21.4 pts | ||
| 3 years | -73.1% | +78.8% | −151.9 pts | -35.4% | +21.4% |
| 5 years | -95.9% | +75.2% | −171.0 pts | -47.1% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cue Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- News
- News
- News
About Cue Biopharma
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical enterprise focused on developing injectable biologic therapies designed to selectively modulate disease-specific T cells. Utilizing its modular Immuno-STAT platform, it seeks to treat autoimmune conditions, inflammatory diseases, and cancers by re-establishing immune balance or clearing pathogenic cells without inducing broad systemic toxicity. Its pipeline includes the CUE-400 series targeting regulatory T cell expansion, the CUE-500 series for targeted pathogenic cell depletion, and the CUE-100 series for oncology applications. As a development-stage entity, the business collaborates with and licenses its candidate molecules to pharmaceutical partners, including Boehringer Ingelheim, ImmunoScape, and LG Chem.
Company profile, executives and historyCue Biopharma stock: common questions
What is Cue Biopharma's stock price?
CUE closed at $18.66 on Nov 11, 2026, down 0.53% on the day. Over the past 52 weeks it traded between $4.97 and $45.50.
What is Cue Biopharma's market cap?
Cue Biopharma was worth $135.55M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CUE's P/E ratio?
Cue Biopharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$26.88), so it has no meaningful P/E ratio.
How much revenue does Cue Biopharma make?
Cue Biopharma reported revenue of $37.65M for the twelve months to Jun 30, 2026, up 354.4% from a year earlier.
Does Cue Biopharma pay a dividend?
No. Cue Biopharma has not paid a cash dividend over the last twelve months.
When does Cue Biopharma report earnings next?
Cue Biopharma is expected to report Q3 FY2026 results on Nov 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CUE stock performed over the past year?
Including dividends, CUE returned -8.9% over the past year, against +12.4% for the S&P 500.
How many CUE shares are sold short?
1M shares were sold short at the latest FINRA report, 14.38% of the float, or 7.6 days of average trading volume.
Who are Cue Biopharma's competitors?
Companies most similar to Cue Biopharma by business, industry and size include NKTR, VTVT, JANX, FHTX, XNCR.
See a number that looks wrong?